All treatment groups showed a considerable reduction in melanin index and modified melasma area and severity index (mMASI) scores, as well as a notable improvement in patients' quality of life. Although both niosomal TXA/NCA cream and conventional TXA/NCA cream were as effective as HQ cream in management of melasma, adverse reactions and relapse were observed in HQ group. Niosomal or conventional TXA/NCA creams are as effective as HQ 4% cream and due to less serious adverse reactions they would be better choices than HQ-containing preparations in hyperpigmentary disorders.
Relevant if you're working with niacinamide, tranexamic acid, hydroquinone for hyperpigmentation.
If you're targeting hyperpigmentation, this research supports adding niacinamide to your AM/PM routine. Effective concentration range: 2% based on this study.
If you're targeting hyperpigmentation, this research supports adding tranexamic_acid to your AM/PM routine. Effective concentration range: 2% based on this study.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
1. Sci Rep. 2025 Nov 28;15(1):42739. doi: 10.1038/s41598-025-26693-8. Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial. Ghasemiyeh P(1), Haghighi NF(2)(3), Dastgheib L(2)(3), Ranjbar S(2)(3), Mohammadi-Samani S(4)(5).
1. Sci Rep. 2025 Nov 28;15(1):42739. doi: 10.1038/s41598-025-26693-8. Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial. Ghasemiyeh P(1), Haghighi NF(2)(3), Dastgheib L(2)(3), Ranjbar S(2)(3), Mohammadi-Samani S(4)(5). Author information: (1)Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. (2)Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. (3)Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. (4)Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. smsamani@sums.ac.ir. (5)Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. smsamani@sums.ac.ir. Melasma is a common hyperpigmentary skin disorder. Because of its high prevalence and serious complications, including negative psychiatric effects, early diagnosis and treatment would be essential. This randomized, double-blind, case-controlled clinical trial compared the efficacy of niosomal tranexamic acid (TXA) 2%/niacinamide (NCA) 2% cream and conventional TXA 5%/NCA 4% cream with topical hydroquinone (HQ) 4% cream as a gold standard in melasma patients. A total of 99 patients were randomly assigned to three groups: Group A received niosomal TXA/NCA cream, Group B received conventional TXA/NCA cream, and Group C received HQ cream for three months. Each patient attended five dermatologist visits to evaluate clinical efficacy. All treatment groups showed a considerable reduction in melanin index and modified melasma area and severity index (mMASI) scores, as well as a notable improvement in patients' quality of life. Although both niosomal TXA/NCA cream and conventional TXA/NCA cream were as effective as HQ cream in management of melasma, adverse reactions and relapse were observed in HQ group. Niosomal or conventional TXA/NCA creams are as effective as HQ 4% cream and due to less serious adverse reactions they would be better choices than HQ-containing preparations in hyperpigmentary disorders. Clinical Trial Registration No.: IRCT20220609055116N1 (Approval date: 07/23/2023). © 2025. The Author(s). DOI: 10.1038/s41598-025-26693-8 PMCID: PMC12663283 PMID: 41315336 [Indexed for MEDLINE] Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests. Ethics declarations: This study was performed according to the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Shiraz University of Medical Sciences [Ethics Approval ID: IR.SUMS.REC.1402.050] and Iranian Registry of Clinical Trials (IRCT) [IRCT Approval ID: IRCT20220609055116N1, approval date: 07/23/2023]. The full clinical trial protocol can be find through https://irct.behdasht.gov.ir/trial/67780 . Consent to participate: Informed consent was obtained from all participants and/or their legal guardians. Consent to publish: Informed consent was obtained from all participants to publish the information/images in an online open access publication.
Original source →Wounds continue to represent a significant public health challenge globally. In recent years, Astragalus mongholicus Bunge, a traditional Chinese botanical drug utilized for wound treatment, has garnered increasing research attention. However, the therapeutic efficacy and safety of this natural botanical drug on wound healing remain poorly understood.
Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD+) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD+ levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD+ precursor. To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.
Nicotinamide (NAM) and Polypodium leucotomos extract (PL) have demonstrated photoprotective effects, but their role in preventing UVA-induced DNA damage in humans remains unclear. To evaluate the effects of oral NAM and PL on UVA-induced erythema and thymidine dimer (TT-dimer) formation. In this intraindividual trial, 50 healthy volunteers (phototypes I-III) were randomized (1:1) to receive either NAM (2000 mg daily) or PL (Heliocare Advanced: 480 mg daily) for 30 days.
This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →